Moderna's mRNA Flu Vaccine Nears FDA Approval Amid Review Uncertainty

The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) is scheduled to meet on June 18, 2026, to review MRNA's mRNA influenza vaccine mFlusiva, making it one of the most consequential biotech regulatory events of the summer . Moderna is seeking full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, with a post-marketing study planned for the older cohort. The FDA has a target action date of August 5, 2026, for its final decision .

The agency's pre-meeting briefing documents concluded there were "no major deficiencies" with the application, sending MRNA shares up more than 6% ahead of the panel, a signal that regulators and the company appear broadly aligned. However, FDA scientists flagged "evidence gaps" in populations at highest risk for severe influenza outcomes, specifically noting that efficacy has not been established in immunocompromised individuals and very frail older adults. The panel will also scrutinize Moderna's choice of a standard-dose comparator rather than a high-dose formulation, a methodological question that could shape the labeling and commercial positioning of mFlusiva .

Approval of mFlusiva would be a pivotal commercial catalyst for Moderna as it builds out its post-COVID pipeline. The mRNA platform's manufacturing flexibility and potential for annual strain updates could position the vaccine as a differentiated entrant in a market dominated by established players like Pfizer and GSK. Advisory committee recommendations are non-binding but the FDA typically follows VRBPAC guidance, making the June 18 panel vote an important near-term signal for investors tracking the August decision deadline.